BRAF and neoplasm: Data analysis was conducted between February 1, 2021, and February 1, 2023.<h4>Exposures</h4>Quantitative VAF assays of BRAF V600E and TERT promoter variants (C228T and C250T) were performed by digital polymerase chain reaction molecular assays.<h4>Main outcomes and measures</h4>The VAFs of BRAF V600E and TERT promoter variants were correlated with tumor histologic diagnoses and histopathologic features to delineate the association of VAF assays with tumor malignancy.